nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CA1—stomach cancer	0.206	0.508	CbGaD
Imatinib—CA2—stomach cancer	0.156	0.385	CbGaD
Imatinib—ALB—stomach cancer	0.0436	0.108	CbGaD
Imatinib—ABCB1—Mitomycin—stomach cancer	0.0261	0.104	CbGbCtD
Imatinib—ABCG2—Irinotecan—stomach cancer	0.0186	0.0743	CbGbCtD
Imatinib—ABCG2—Fluorouracil—stomach cancer	0.0178	0.0713	CbGbCtD
Imatinib—CYP3A7—Irinotecan—stomach cancer	0.0137	0.0549	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Irinotecan—stomach cancer	0.0137	0.0549	CbGbCtD
Imatinib—ABCG2—Docetaxel—stomach cancer	0.0136	0.0545	CbGbCtD
Imatinib—ALB—Irinotecan—stomach cancer	0.0128	0.0512	CbGbCtD
Imatinib—ALB—Fluorouracil—stomach cancer	0.0123	0.0492	CbGbCtD
Imatinib—CYP2C9—Capecitabine—stomach cancer	0.0112	0.0447	CbGbCtD
Imatinib—CYP3A5—Irinotecan—stomach cancer	0.0103	0.0412	CbGbCtD
Imatinib—ABCG2—Doxorubicin—stomach cancer	0.0101	0.0406	CbGbCtD
Imatinib—CYP3A7—Docetaxel—stomach cancer	0.01	0.0402	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—stomach cancer	0.01	0.0402	CbGbCtD
Imatinib—ABCG2—Methotrexate—stomach cancer	0.00982	0.0393	CbGbCtD
Imatinib—CYP3A5—Docetaxel—stomach cancer	0.00753	0.0302	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—stomach cancer	0.00734	0.0294	CbGbCtD
Imatinib—ALB—Methotrexate—stomach cancer	0.00677	0.0271	CbGbCtD
Imatinib—ABCB1—Irinotecan—stomach cancer	0.00669	0.0268	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—stomach cancer	0.00662	0.0265	CbGbCtD
Imatinib—ABCB1—Docetaxel—stomach cancer	0.0049	0.0196	CbGbCtD
Imatinib—KIT—myenteric nerve plexus—stomach cancer	0.00469	0.0712	CbGeAlD
Imatinib—CYP3A4—Irinotecan—stomach cancer	0.00401	0.0161	CbGbCtD
Imatinib—ABCB1—Doxorubicin—stomach cancer	0.00365	0.0146	CbGbCtD
Imatinib—ABCB1—Methotrexate—stomach cancer	0.00354	0.0142	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—stomach cancer	0.00344	0.0138	CbGbCtD
Imatinib—ORM1—bile—stomach cancer	0.00298	0.0452	CbGeAlD
Imatinib—CYP3A4—Docetaxel—stomach cancer	0.00294	0.0118	CbGbCtD
Imatinib—CYP3A4—Doxorubicin—stomach cancer	0.00219	0.00877	CbGbCtD
Imatinib—Nilotinib—MAPK8—stomach cancer	0.00141	0.358	CrCbGaD
Imatinib—CA9—gall bladder—stomach cancer	0.00141	0.0214	CbGeAlD
Imatinib—Ponatinib—FGFR2—stomach cancer	0.00138	0.35	CrCbGaD
Imatinib—DDR1—smooth muscle tissue—stomach cancer	0.00125	0.0189	CbGeAlD
Imatinib—DDR1—pancreas—stomach cancer	0.00115	0.0175	CbGeAlD
Imatinib—PDGFRA—gall bladder—stomach cancer	0.00113	0.0171	CbGeAlD
Imatinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.00112	0.424	CbGdCrCtD
Imatinib—KIT—blood vessel—stomach cancer	0.00096	0.0146	CbGeAlD
Imatinib—PDGFRB—blood vessel—stomach cancer	0.000937	0.0142	CbGeAlD
Imatinib—KIT—gall bladder—stomach cancer	0.000903	0.0137	CbGeAlD
Imatinib—HIPK4—endocrine gland—stomach cancer	0.00089	0.0135	CbGeAlD
Imatinib—PDGFRB—gall bladder—stomach cancer	0.000882	0.0134	CbGeAlD
Imatinib—ORM1—gall bladder—stomach cancer	0.000827	0.0125	CbGeAlD
Imatinib—DDR1—liver—stomach cancer	0.000732	0.0111	CbGeAlD
Imatinib—ALB—gall bladder—stomach cancer	0.000726	0.011	CbGeAlD
Imatinib—PIP4K2C—pancreas—stomach cancer	0.000711	0.0108	CbGeAlD
Imatinib—Nilotinib—CA1—stomach cancer	0.000655	0.166	CrCbGaD
Imatinib—PDGFRA—hematopoietic system—stomach cancer	0.000639	0.0097	CbGeAlD
Imatinib—CA7—digestive system—stomach cancer	0.000632	0.00958	CbGeAlD
Imatinib—ABCA3—lymph node—stomach cancer	0.000609	0.00923	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—stomach cancer	0.000563	0.00854	CbGeAlD
Imatinib—CSF1R—hematopoietic system—stomach cancer	0.000563	0.00854	CbGeAlD
Imatinib—DDR1—lymph node—stomach cancer	0.000562	0.00852	CbGeAlD
Imatinib—PIP4K2C—bone marrow—stomach cancer	0.000559	0.00848	CbGeAlD
Imatinib—CA9—digestive system—stomach cancer	0.000555	0.00841	CbGeAlD
Imatinib—CA2—gall bladder—stomach cancer	0.000535	0.00812	CbGeAlD
Imatinib—CA3—bone marrow—stomach cancer	0.000534	0.0081	CbGeAlD
Imatinib—NQO2—pancreas—stomach cancer	0.000522	0.00791	CbGeAlD
Imatinib—SLC47A1—hematopoietic system—stomach cancer	0.000514	0.0078	CbGeAlD
Imatinib—KIT—hematopoietic system—stomach cancer	0.000511	0.00775	CbGeAlD
Imatinib—PIP4K2C—endocrine gland—stomach cancer	0.000501	0.0076	CbGeAlD
Imatinib—PDGFRB—hematopoietic system—stomach cancer	0.000499	0.00757	CbGeAlD
Imatinib—LCK—bone marrow—stomach cancer	0.000497	0.00753	CbGeAlD
Imatinib—Nilotinib—CA2—stomach cancer	0.000496	0.126	CrCbGaD
Imatinib—CSF1R—smooth muscle tissue—stomach cancer	0.000496	0.00752	CbGeAlD
Imatinib—CA3—endocrine gland—stomach cancer	0.000479	0.00726	CbGeAlD
Imatinib—ABL2—liver—stomach cancer	0.000478	0.00725	CbGeAlD
Imatinib—ORM1—hematopoietic system—stomach cancer	0.000468	0.0071	CbGeAlD
Imatinib—CA1—hematopoietic system—stomach cancer	0.000467	0.00709	CbGeAlD
Imatinib—KIT—epithelium—stomach cancer	0.000467	0.00708	CbGeAlD
Imatinib—CA9—endocrine gland—stomach cancer	0.000458	0.00695	CbGeAlD
Imatinib—PDGFRB—epithelium—stomach cancer	0.000456	0.00692	CbGeAlD
Imatinib—PIP4K2C—liver—stomach cancer	0.000452	0.00686	CbGeAlD
Imatinib—KIT—smooth muscle tissue—stomach cancer	0.00045	0.00683	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—stomach cancer	0.00045	0.00683	CbGeAlD
Imatinib—ABL1—hematopoietic system—stomach cancer	0.000445	0.00675	CbGeAlD
Imatinib—PDGFRA—digestive system—stomach cancer	0.000445	0.00674	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—stomach cancer	0.00044	0.00667	CbGeAlD
Imatinib—PTGS1—blood vessel—stomach cancer	0.000439	0.00666	CbGeAlD
Imatinib—CA3—liver—stomach cancer	0.000432	0.00655	CbGeAlD
Imatinib—CYP3A7—endocrine gland—stomach cancer	0.000425	0.00645	CbGeAlD
Imatinib—SLC22A2—digestive system—stomach cancer	0.000422	0.0064	CbGeAlD
Imatinib—KIT—pancreas—stomach cancer	0.000416	0.00631	CbGeAlD
Imatinib—NQO2—bone marrow—stomach cancer	0.000411	0.00623	CbGeAlD
Imatinib—CA12—digestive system—stomach cancer	0.00041	0.00622	CbGeAlD
Imatinib—PDGFRB—pancreas—stomach cancer	0.000406	0.00616	CbGeAlD
Imatinib—LCK—liver—stomach cancer	0.000401	0.00609	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—stomach cancer	0.000396	0.00601	CbGeAlD
Imatinib—CA14—liver—stomach cancer	0.000392	0.00594	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—stomach cancer	0.000392	0.00594	CbGeAlD
Imatinib—CSF1R—digestive system—stomach cancer	0.000391	0.00594	CbGeAlD
Imatinib—CYP3A7—liver—stomach cancer	0.000383	0.00581	CbGeAlD
Imatinib—CA1—pancreas—stomach cancer	0.000381	0.00577	CbGeAlD
Imatinib—NQO2—endocrine gland—stomach cancer	0.000368	0.00559	CbGeAlD
Imatinib—PDGFRA—endocrine gland—stomach cancer	0.000367	0.00557	CbGeAlD
Imatinib—ABL2—lymph node—stomach cancer	0.000366	0.00556	CbGeAlD
Imatinib—ABL1—pancreas—stomach cancer	0.000362	0.00549	CbGeAlD
Imatinib—CSF1R—bone marrow—stomach cancer	0.000361	0.00547	CbGeAlD
Imatinib—KIT—lymphoid tissue—stomach cancer	0.00036	0.00546	CbGeAlD
Imatinib—SLC47A1—digestive system—stomach cancer	0.000357	0.00542	CbGeAlD
Imatinib—KIT—digestive system—stomach cancer	0.000355	0.00539	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—stomach cancer	0.000351	0.00533	CbGeAlD
Imatinib—PDGFRB—digestive system—stomach cancer	0.000347	0.00526	CbGeAlD
Imatinib—PIP4K2C—lymph node—stomach cancer	0.000347	0.00526	CbGeAlD
Imatinib—CA12—endocrine gland—stomach cancer	0.000339	0.00514	CbGeAlD
Imatinib—NQO2—liver—stomach cancer	0.000332	0.00504	CbGeAlD
Imatinib—PDGFRA—liver—stomach cancer	0.000331	0.00502	CbGeAlD
Imatinib—CA3—lymph node—stomach cancer	0.000331	0.00502	CbGeAlD
Imatinib—CYP2C19—hematopoietic system—stomach cancer	0.000331	0.00501	CbGeAlD
Imatinib—CA1—lymphoid tissue—stomach cancer	0.000329	0.00499	CbGeAlD
Imatinib—KIT—bone marrow—stomach cancer	0.000328	0.00497	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—stomach cancer	0.000326	0.00494	CbGeAlD
Imatinib—CA1—digestive system—stomach cancer	0.000325	0.00493	CbGeAlD
Imatinib—CSF1R—endocrine gland—stomach cancer	0.000323	0.0049	CbGeAlD
Imatinib—PDGFRB—bone marrow—stomach cancer	0.00032	0.00485	CbGeAlD
Imatinib—ABL1—lymphoid tissue—stomach cancer	0.000313	0.00475	CbGeAlD
Imatinib—ABL1—digestive system—stomach cancer	0.000309	0.00469	CbGeAlD
Imatinib—LCK—lymph node—stomach cancer	0.000308	0.00467	CbGeAlD
Imatinib—CA2—hematopoietic system—stomach cancer	0.000303	0.00459	CbGeAlD
Imatinib—ORM1—bone marrow—stomach cancer	0.0003	0.00455	CbGeAlD
Imatinib—CA1—bone marrow—stomach cancer	0.0003	0.00454	CbGeAlD
Imatinib—SLC47A1—endocrine gland—stomach cancer	0.000295	0.00448	CbGeAlD
Imatinib—KIT—endocrine gland—stomach cancer	0.000294	0.00445	CbGeAlD
Imatinib—CSF1R—liver—stomach cancer	0.000292	0.00442	CbGeAlD
Imatinib—PDGFRB—endocrine gland—stomach cancer	0.000287	0.00435	CbGeAlD
Imatinib—ABL1—bone marrow—stomach cancer	0.000285	0.00433	CbGeAlD
Imatinib—CA2—epithelium—stomach cancer	0.000277	0.0042	CbGeAlD
Imatinib—CYP1A2—hematopoietic system—stomach cancer	0.00027	0.00409	CbGeAlD
Imatinib—ORM1—endocrine gland—stomach cancer	0.000269	0.00408	CbGeAlD
Imatinib—CA1—endocrine gland—stomach cancer	0.000269	0.00407	CbGeAlD
Imatinib—CA2—smooth muscle tissue—stomach cancer	0.000267	0.00405	CbGeAlD
Imatinib—SLC47A1—liver—stomach cancer	0.000266	0.00404	CbGeAlD
Imatinib—KIT—liver—stomach cancer	0.000265	0.00402	CbGeAlD
Imatinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000263	0.0997	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000263	0.0997	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000263	0.0997	CbGdCrCtD
Imatinib—CYP3A5—hematopoietic system—stomach cancer	0.00026	0.00395	CbGeAlD
Imatinib—ABCB1—blood vessel—stomach cancer	0.00026	0.00394	CbGeAlD
Imatinib—PDGFRB—liver—stomach cancer	0.000259	0.00392	CbGeAlD
Imatinib—CYP2C9—hematopoietic system—stomach cancer	0.000256	0.00389	CbGeAlD
Imatinib—ABL1—endocrine gland—stomach cancer	0.000256	0.00388	CbGeAlD
Imatinib—NQO2—lymph node—stomach cancer	0.000255	0.00386	CbGeAlD
Imatinib—PDGFRA—lymph node—stomach cancer	0.000254	0.00385	CbGeAlD
Imatinib—CA2—pancreas—stomach cancer	0.000247	0.00374	CbGeAlD
Imatinib—SLC22A1—endocrine gland—stomach cancer	0.000246	0.00374	CbGeAlD
Imatinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000243	0.0923	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000243	0.0923	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000243	0.0923	CbGdCrCtD
Imatinib—ORM1—liver—stomach cancer	0.000243	0.00368	CbGeAlD
Imatinib—CA1—liver—stomach cancer	0.000242	0.00367	CbGeAlD
Imatinib—PTGS1—hematopoietic system—stomach cancer	0.000234	0.00355	CbGeAlD
Imatinib—ABL1—liver—stomach cancer	0.000231	0.0035	CbGeAlD
Imatinib—CYP2C19—digestive system—stomach cancer	0.00023	0.00349	CbGeAlD
Imatinib—CSF1R—lymph node—stomach cancer	0.000224	0.00339	CbGeAlD
Imatinib—SLC22A1—liver—stomach cancer	0.000222	0.00337	CbGeAlD
Imatinib—PTGS1—epithelium—stomach cancer	0.000214	0.00324	CbGeAlD
Imatinib—CA2—lymphoid tissue—stomach cancer	0.000213	0.00323	CbGeAlD
Imatinib—ALB—liver—stomach cancer	0.000213	0.00323	CbGeAlD
Imatinib—CYP3A5—pancreas—stomach cancer	0.000212	0.00322	CbGeAlD
Imatinib—CA2—digestive system—stomach cancer	0.000211	0.0032	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—stomach cancer	0.000206	0.00313	CbGeAlD
Imatinib—SLC47A1—lymph node—stomach cancer	0.000204	0.0031	CbGeAlD
Imatinib—KIT—lymph node—stomach cancer	0.000203	0.00308	CbGeAlD
Imatinib—PDGFRB—lymph node—stomach cancer	0.000198	0.00301	CbGeAlD
Imatinib—CYP3A4—hematopoietic system—stomach cancer	0.000195	0.00296	CbGeAlD
Imatinib—CA2—bone marrow—stomach cancer	0.000194	0.00295	CbGeAlD
Imatinib—CYP2D6—hematopoietic system—stomach cancer	0.000192	0.00292	CbGeAlD
Imatinib—CYP2C19—endocrine gland—stomach cancer	0.00019	0.00288	CbGeAlD
Imatinib—CYP1A2—digestive system—stomach cancer	0.000188	0.00285	CbGeAlD
Imatinib—ORM1—lymph node—stomach cancer	0.000186	0.00282	CbGeAlD
Imatinib—CA1—lymph node—stomach cancer	0.000186	0.00282	CbGeAlD
Imatinib—CYP3A5—digestive system—stomach cancer	0.000181	0.00275	CbGeAlD
Imatinib—ABCG2—bone marrow—stomach cancer	0.00018	0.00273	CbGeAlD
Imatinib—CYP2C9—digestive system—stomach cancer	0.000178	0.0027	CbGeAlD
Imatinib—ABL1—lymph node—stomach cancer	0.000177	0.00268	CbGeAlD
Imatinib—CA2—endocrine gland—stomach cancer	0.000174	0.00264	CbGeAlD
Imatinib—CYP2C19—liver—stomach cancer	0.000171	0.0026	CbGeAlD
Imatinib—ALB—lymph node—stomach cancer	0.000163	0.00247	CbGeAlD
Imatinib—PTGS1—digestive system—stomach cancer	0.000163	0.00247	CbGeAlD
Imatinib—CA2—liver—stomach cancer	0.000157	0.00238	CbGeAlD
Imatinib—CYP1A2—endocrine gland—stomach cancer	0.000155	0.00235	CbGeAlD
Imatinib—CYP3A5—endocrine gland—stomach cancer	0.00015	0.00227	CbGeAlD
Imatinib—CYP2C9—endocrine gland—stomach cancer	0.000147	0.00223	CbGeAlD
Imatinib—ABCG2—liver—stomach cancer	0.000145	0.0022	CbGeAlD
Imatinib—CYP1A2—liver—stomach cancer	0.00014	0.00212	CbGeAlD
Imatinib—ABCB1—hematopoietic system—stomach cancer	0.000138	0.0021	CbGeAlD
Imatinib—CYP3A4—digestive system—stomach cancer	0.000136	0.00206	CbGeAlD
Imatinib—CYP3A5—liver—stomach cancer	0.000135	0.00205	CbGeAlD
Imatinib—PTGS1—endocrine gland—stomach cancer	0.000134	0.00204	CbGeAlD
Imatinib—CYP2D6—digestive system—stomach cancer	0.000134	0.00203	CbGeAlD
Imatinib—CYP2C9—liver—stomach cancer	0.000133	0.00201	CbGeAlD
Imatinib—ABCB1—epithelium—stomach cancer	0.000126	0.00192	CbGeAlD
Imatinib—CA2—lymph node—stomach cancer	0.00012	0.00183	CbGeAlD
Imatinib—ABCB1—pancreas—stomach cancer	0.000113	0.00171	CbGeAlD
Imatinib—CYP3A4—endocrine gland—stomach cancer	0.000112	0.0017	CbGeAlD
Imatinib—ABCG2—lymph node—stomach cancer	0.000111	0.00169	CbGeAlD
Imatinib—CYP2D6—endocrine gland—stomach cancer	0.000111	0.00168	CbGeAlD
Imatinib—CYP3A4—liver—stomach cancer	0.000101	0.00154	CbGeAlD
Imatinib—CYP2D6—liver—stomach cancer	9.96e-05	0.00151	CbGeAlD
Imatinib—ABCB1—lymphoid tissue—stomach cancer	9.74e-05	0.00148	CbGeAlD
Imatinib—ABCB1—digestive system—stomach cancer	9.62e-05	0.00146	CbGeAlD
Imatinib—PTGS1—lymph node—stomach cancer	9.3e-05	0.00141	CbGeAlD
Imatinib—ABCB1—bone marrow—stomach cancer	8.87e-05	0.00135	CbGeAlD
Imatinib—ABCB1—endocrine gland—stomach cancer	7.95e-05	0.00121	CbGeAlD
Imatinib—ABCB1—liver—stomach cancer	7.17e-05	0.00109	CbGeAlD
Imatinib—ABCB1—lymph node—stomach cancer	5.5e-05	0.000833	CbGeAlD
Imatinib—Hepatitis—Doxorubicin—stomach cancer	4.55e-05	0.000303	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—stomach cancer	4.55e-05	0.000303	CcSEcCtD
Imatinib—Insomnia—Capecitabine—stomach cancer	4.53e-05	0.000303	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—stomach cancer	4.52e-05	0.000302	CcSEcCtD
Imatinib—Rash—Fluorouracil—stomach cancer	4.52e-05	0.000302	CcSEcCtD
Imatinib—Dermatitis—Fluorouracil—stomach cancer	4.52e-05	0.000302	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—stomach cancer	4.51e-05	0.000301	CcSEcCtD
Imatinib—Paraesthesia—Capecitabine—stomach cancer	4.5e-05	0.0003	CcSEcCtD
Imatinib—Decreased appetite—Docetaxel—stomach cancer	4.5e-05	0.0003	CcSEcCtD
Imatinib—Headache—Fluorouracil—stomach cancer	4.49e-05	0.0003	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—stomach cancer	4.49e-05	0.0003	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—stomach cancer	4.48e-05	0.000299	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—stomach cancer	4.48e-05	0.000299	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—stomach cancer	4.47e-05	0.000298	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—stomach cancer	4.47e-05	0.000298	CcSEcCtD
Imatinib—Dyspnoea—Capecitabine—stomach cancer	4.47e-05	0.000298	CcSEcCtD
Imatinib—Fatigue—Docetaxel—stomach cancer	4.46e-05	0.000298	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—stomach cancer	4.46e-05	0.000298	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—stomach cancer	4.46e-05	0.000297	CcSEcCtD
Imatinib—Nausea—Irinotecan—stomach cancer	4.45e-05	0.000297	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—stomach cancer	4.44e-05	0.000296	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—stomach cancer	4.43e-05	0.000296	CcSEcCtD
Imatinib—Pain—Docetaxel—stomach cancer	4.43e-05	0.000295	CcSEcCtD
Imatinib—Constipation—Docetaxel—stomach cancer	4.43e-05	0.000295	CcSEcCtD
Imatinib—Back pain—Methotrexate—stomach cancer	4.42e-05	0.000295	CcSEcCtD
Imatinib—Dyspepsia—Capecitabine—stomach cancer	4.41e-05	0.000294	CcSEcCtD
Imatinib—Chills—Epirubicin—stomach cancer	4.41e-05	0.000294	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—stomach cancer	4.39e-05	0.000293	CcSEcCtD
Imatinib—Decreased appetite—Capecitabine—stomach cancer	4.36e-05	0.000291	CcSEcCtD
Imatinib—Alopecia—Epirubicin—stomach cancer	4.34e-05	0.00029	CcSEcCtD
Imatinib—Gastrointestinal disorder—Capecitabine—stomach cancer	4.33e-05	0.000289	CcSEcCtD
Imatinib—Fatigue—Capecitabine—stomach cancer	4.32e-05	0.000288	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—stomach cancer	4.31e-05	0.000288	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—stomach cancer	4.31e-05	0.000287	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—stomach cancer	4.3e-05	0.000287	CcSEcCtD
Imatinib—Pain—Capecitabine—stomach cancer	4.29e-05	0.000286	CcSEcCtD
Imatinib—Constipation—Capecitabine—stomach cancer	4.29e-05	0.000286	CcSEcCtD
Imatinib—Erythema—Epirubicin—stomach cancer	4.28e-05	0.000286	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—stomach cancer	4.28e-05	0.000286	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—stomach cancer	4.27e-05	0.000285	CcSEcCtD
Imatinib—Nausea—Fluorouracil—stomach cancer	4.26e-05	0.000284	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—stomach cancer	4.25e-05	0.000284	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—stomach cancer	4.24e-05	0.000283	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—stomach cancer	4.24e-05	0.000283	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—stomach cancer	4.23e-05	0.000282	CcSEcCtD
Imatinib—Anaemia—Methotrexate—stomach cancer	4.23e-05	0.000282	CcSEcCtD
Imatinib—Flushing—Doxorubicin—stomach cancer	4.22e-05	0.000282	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—stomach cancer	4.22e-05	0.000282	CcSEcCtD
Imatinib—Flatulence—Epirubicin—stomach cancer	4.22e-05	0.000281	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—stomach cancer	4.19e-05	0.00028	CcSEcCtD
Imatinib—Back pain—Epirubicin—stomach cancer	4.14e-05	0.000276	CcSEcCtD
Imatinib—Feeling abnormal—Capecitabine—stomach cancer	4.13e-05	0.000276	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—stomach cancer	4.13e-05	0.000275	CcSEcCtD
Imatinib—Malaise—Methotrexate—stomach cancer	4.12e-05	0.000275	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—stomach cancer	4.11e-05	0.000275	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—stomach cancer	4.11e-05	0.000274	CcSEcCtD
Imatinib—Vertigo—Methotrexate—stomach cancer	4.11e-05	0.000274	CcSEcCtD
Imatinib—Gastrointestinal pain—Capecitabine—stomach cancer	4.1e-05	0.000274	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—stomach cancer	4.1e-05	0.000274	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—stomach cancer	4.09e-05	0.000273	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—stomach cancer	4.09e-05	0.000273	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—stomach cancer	4.09e-05	0.000273	CcSEcCtD
Imatinib—Chills—Doxorubicin—stomach cancer	4.08e-05	0.000272	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—stomach cancer	4.06e-05	0.000271	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—stomach cancer	4.03e-05	0.000269	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—stomach cancer	4.02e-05	0.000268	CcSEcCtD
Imatinib—Cough—Methotrexate—stomach cancer	3.99e-05	0.000266	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—stomach cancer	3.98e-05	0.000266	CcSEcCtD
Imatinib—Urticaria—Capecitabine—stomach cancer	3.98e-05	0.000266	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—stomach cancer	3.97e-05	0.000265	CcSEcCtD
Imatinib—Abdominal pain—Capecitabine—stomach cancer	3.96e-05	0.000264	CcSEcCtD
Imatinib—Body temperature increased—Capecitabine—stomach cancer	3.96e-05	0.000264	CcSEcCtD
Imatinib—Convulsion—Methotrexate—stomach cancer	3.96e-05	0.000264	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—stomach cancer	3.96e-05	0.000264	CcSEcCtD
Imatinib—Erythema—Doxorubicin—stomach cancer	3.96e-05	0.000264	CcSEcCtD
Imatinib—Anaemia—Epirubicin—stomach cancer	3.95e-05	0.000264	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—stomach cancer	3.9e-05	0.00026	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—stomach cancer	3.89e-05	0.00026	CcSEcCtD
Imatinib—Myalgia—Methotrexate—stomach cancer	3.89e-05	0.00026	CcSEcCtD
Imatinib—Chest pain—Methotrexate—stomach cancer	3.89e-05	0.00026	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—stomach cancer	3.88e-05	0.000259	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.87e-05	0.000258	CcSEcCtD
Imatinib—Malaise—Epirubicin—stomach cancer	3.86e-05	0.000257	CcSEcCtD
Imatinib—Discomfort—Methotrexate—stomach cancer	3.85e-05	0.000257	CcSEcCtD
Imatinib—Vertigo—Epirubicin—stomach cancer	3.84e-05	0.000257	CcSEcCtD
Imatinib—Syncope—Epirubicin—stomach cancer	3.84e-05	0.000256	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—stomach cancer	3.83e-05	0.000256	CcSEcCtD
Imatinib—Back pain—Doxorubicin—stomach cancer	3.83e-05	0.000256	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—stomach cancer	3.81e-05	0.000255	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—stomach cancer	3.81e-05	0.000254	CcSEcCtD
Imatinib—Palpitations—Epirubicin—stomach cancer	3.78e-05	0.000252	CcSEcCtD
Imatinib—Confusional state—Methotrexate—stomach cancer	3.76e-05	0.000251	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—stomach cancer	3.76e-05	0.000251	CcSEcCtD
Imatinib—Cough—Epirubicin—stomach cancer	3.73e-05	0.000249	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—stomach cancer	3.73e-05	0.000249	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—stomach cancer	3.73e-05	0.000249	CcSEcCtD
Imatinib—Asthenia—Docetaxel—stomach cancer	3.71e-05	0.000248	CcSEcCtD
Imatinib—Convulsion—Epirubicin—stomach cancer	3.71e-05	0.000247	CcSEcCtD
Imatinib—Infection—Methotrexate—stomach cancer	3.71e-05	0.000247	CcSEcCtD
Imatinib—Hypertension—Epirubicin—stomach cancer	3.69e-05	0.000247	CcSEcCtD
Imatinib—Hypersensitivity—Capecitabine—stomach cancer	3.69e-05	0.000246	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—stomach cancer	3.67e-05	0.000245	CcSEcCtD
Imatinib—Pruritus—Docetaxel—stomach cancer	3.66e-05	0.000244	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—stomach cancer	3.66e-05	0.000244	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—stomach cancer	3.66e-05	0.000244	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—stomach cancer	3.65e-05	0.000244	CcSEcCtD
Imatinib—Chest pain—Epirubicin—stomach cancer	3.64e-05	0.000243	CcSEcCtD
Imatinib—Myalgia—Epirubicin—stomach cancer	3.64e-05	0.000243	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—stomach cancer	3.64e-05	0.000243	CcSEcCtD
Imatinib—Anxiety—Epirubicin—stomach cancer	3.63e-05	0.000242	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—stomach cancer	3.62e-05	0.000242	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.62e-05	0.000241	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—stomach cancer	3.61e-05	0.000241	CcSEcCtD
Imatinib—Discomfort—Epirubicin—stomach cancer	3.6e-05	0.00024	CcSEcCtD
Imatinib—Asthenia—Capecitabine—stomach cancer	3.6e-05	0.00024	CcSEcCtD
Imatinib—Malaise—Doxorubicin—stomach cancer	3.57e-05	0.000238	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—stomach cancer	3.56e-05	0.000238	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—stomach cancer	3.56e-05	0.000237	CcSEcCtD
Imatinib—Anorexia—Methotrexate—stomach cancer	3.56e-05	0.000237	CcSEcCtD
Imatinib—Syncope—Doxorubicin—stomach cancer	3.55e-05	0.000237	CcSEcCtD
Imatinib—Pruritus—Capecitabine—stomach cancer	3.55e-05	0.000237	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—stomach cancer	3.54e-05	0.000236	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—stomach cancer	3.54e-05	0.000236	CcSEcCtD
Imatinib—Confusional state—Epirubicin—stomach cancer	3.52e-05	0.000235	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—stomach cancer	3.5e-05	0.000233	CcSEcCtD
Imatinib—Oedema—Epirubicin—stomach cancer	3.49e-05	0.000233	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—stomach cancer	3.49e-05	0.000233	CcSEcCtD
Imatinib—Hypotension—Methotrexate—stomach cancer	3.49e-05	0.000233	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—stomach cancer	3.48e-05	0.000232	CcSEcCtD
Imatinib—Infection—Epirubicin—stomach cancer	3.47e-05	0.000231	CcSEcCtD
Imatinib—Cough—Doxorubicin—stomach cancer	3.45e-05	0.000231	CcSEcCtD
Imatinib—Shock—Epirubicin—stomach cancer	3.44e-05	0.000229	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—stomach cancer	3.43e-05	0.000229	CcSEcCtD
Imatinib—Diarrhoea—Capecitabine—stomach cancer	3.43e-05	0.000229	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—stomach cancer	3.42e-05	0.000229	CcSEcCtD
Imatinib—Dizziness—Docetaxel—stomach cancer	3.42e-05	0.000228	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—stomach cancer	3.42e-05	0.000228	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—stomach cancer	3.42e-05	0.000228	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—stomach cancer	3.41e-05	0.000227	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.4e-05	0.000227	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—stomach cancer	3.39e-05	0.000226	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—stomach cancer	3.38e-05	0.000225	CcSEcCtD
Imatinib—Insomnia—Methotrexate—stomach cancer	3.37e-05	0.000225	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—stomach cancer	3.37e-05	0.000225	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—stomach cancer	3.37e-05	0.000225	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—stomach cancer	3.37e-05	0.000225	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—stomach cancer	3.36e-05	0.000224	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—stomach cancer	3.35e-05	0.000224	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.35e-05	0.000223	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—stomach cancer	3.33e-05	0.000222	CcSEcCtD
Imatinib—Anorexia—Epirubicin—stomach cancer	3.33e-05	0.000222	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—stomach cancer	3.33e-05	0.000222	CcSEcCtD
Imatinib—Somnolence—Methotrexate—stomach cancer	3.32e-05	0.000221	CcSEcCtD
Imatinib—Dizziness—Capecitabine—stomach cancer	3.31e-05	0.000221	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—stomach cancer	3.3e-05	0.00022	CcSEcCtD
Imatinib—Vomiting—Docetaxel—stomach cancer	3.29e-05	0.00022	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—stomach cancer	3.28e-05	0.000219	CcSEcCtD
Imatinib—Rash—Docetaxel—stomach cancer	3.26e-05	0.000218	CcSEcCtD
Imatinib—Hypotension—Epirubicin—stomach cancer	3.26e-05	0.000218	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—stomach cancer	3.26e-05	0.000218	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—stomach cancer	3.26e-05	0.000217	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—stomach cancer	3.24e-05	0.000216	CcSEcCtD
Imatinib—Headache—Docetaxel—stomach cancer	3.24e-05	0.000216	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—stomach cancer	3.23e-05	0.000216	CcSEcCtD
Imatinib—Oedema—Doxorubicin—stomach cancer	3.23e-05	0.000216	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—stomach cancer	3.22e-05	0.000215	CcSEcCtD
Imatinib—Fatigue—Methotrexate—stomach cancer	3.22e-05	0.000215	CcSEcCtD
Imatinib—Infection—Doxorubicin—stomach cancer	3.21e-05	0.000214	CcSEcCtD
Imatinib—Pain—Methotrexate—stomach cancer	3.19e-05	0.000213	CcSEcCtD
Imatinib—Vomiting—Capecitabine—stomach cancer	3.19e-05	0.000213	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	3.18e-05	0.000212	CcSEcCtD
Imatinib—Shock—Doxorubicin—stomach cancer	3.18e-05	0.000212	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—stomach cancer	3.17e-05	0.000211	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—stomach cancer	3.16e-05	0.000211	CcSEcCtD
Imatinib—Rash—Capecitabine—stomach cancer	3.16e-05	0.000211	CcSEcCtD
Imatinib—Insomnia—Epirubicin—stomach cancer	3.16e-05	0.000211	CcSEcCtD
Imatinib—Dermatitis—Capecitabine—stomach cancer	3.16e-05	0.000211	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—stomach cancer	3.15e-05	0.00021	CcSEcCtD
Imatinib—Headache—Capecitabine—stomach cancer	3.14e-05	0.00021	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—stomach cancer	3.14e-05	0.000209	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—stomach cancer	3.14e-05	0.000209	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—stomach cancer	3.12e-05	0.000208	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—stomach cancer	3.11e-05	0.000208	CcSEcCtD
Imatinib—Somnolence—Epirubicin—stomach cancer	3.1e-05	0.000207	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—stomach cancer	3.08e-05	0.000206	CcSEcCtD
Imatinib—Nausea—Docetaxel—stomach cancer	3.07e-05	0.000205	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—stomach cancer	3.07e-05	0.000205	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—stomach cancer	3.07e-05	0.000205	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—stomach cancer	3.05e-05	0.000204	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—stomach cancer	3.04e-05	0.000203	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—stomach cancer	3.02e-05	0.000201	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—stomach cancer	3.01e-05	0.000201	CcSEcCtD
Imatinib—Fatigue—Epirubicin—stomach cancer	3.01e-05	0.000201	CcSEcCtD
Imatinib—Pain—Epirubicin—stomach cancer	2.99e-05	0.000199	CcSEcCtD
Imatinib—Constipation—Epirubicin—stomach cancer	2.99e-05	0.000199	CcSEcCtD
Imatinib—Nausea—Capecitabine—stomach cancer	2.98e-05	0.000199	CcSEcCtD
Imatinib—Urticaria—Methotrexate—stomach cancer	2.96e-05	0.000198	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—stomach cancer	2.95e-05	0.000197	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—stomach cancer	2.95e-05	0.000197	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	2.94e-05	0.000196	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—stomach cancer	2.92e-05	0.000195	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—stomach cancer	2.9e-05	0.000194	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—stomach cancer	2.88e-05	0.000192	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—stomach cancer	2.88e-05	0.000192	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—stomach cancer	2.87e-05	0.000192	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—stomach cancer	2.86e-05	0.000191	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—stomach cancer	2.84e-05	0.00019	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—stomach cancer	2.81e-05	0.000187	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.79e-05	0.000186	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—stomach cancer	2.79e-05	0.000186	CcSEcCtD
Imatinib—Urticaria—Epirubicin—stomach cancer	2.77e-05	0.000185	CcSEcCtD
Imatinib—Pain—Doxorubicin—stomach cancer	2.76e-05	0.000184	CcSEcCtD
Imatinib—Constipation—Doxorubicin—stomach cancer	2.76e-05	0.000184	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—stomach cancer	2.76e-05	0.000184	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—stomach cancer	2.76e-05	0.000184	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—stomach cancer	2.75e-05	0.000183	CcSEcCtD
Imatinib—Asthenia—Methotrexate—stomach cancer	2.68e-05	0.000179	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—stomach cancer	2.66e-05	0.000178	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—stomach cancer	2.64e-05	0.000176	CcSEcCtD
Imatinib—Pruritus—Methotrexate—stomach cancer	2.64e-05	0.000176	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—stomach cancer	2.57e-05	0.000172	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—stomach cancer	2.57e-05	0.000171	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—stomach cancer	2.55e-05	0.00017	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—stomach cancer	2.55e-05	0.00017	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—stomach cancer	2.55e-05	0.00017	CcSEcCtD
Imatinib—Asthenia—Epirubicin—stomach cancer	2.51e-05	0.000167	CcSEcCtD
Imatinib—Pruritus—Epirubicin—stomach cancer	2.47e-05	0.000165	CcSEcCtD
Imatinib—Dizziness—Methotrexate—stomach cancer	2.47e-05	0.000165	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—stomach cancer	2.39e-05	0.000159	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—stomach cancer	2.38e-05	0.000159	CcSEcCtD
Imatinib—Vomiting—Methotrexate—stomach cancer	2.37e-05	0.000158	CcSEcCtD
Imatinib—Rash—Methotrexate—stomach cancer	2.35e-05	0.000157	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—stomach cancer	2.35e-05	0.000157	CcSEcCtD
Imatinib—Headache—Methotrexate—stomach cancer	2.34e-05	0.000156	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—stomach cancer	2.32e-05	0.000155	CcSEcCtD
Imatinib—Dizziness—Epirubicin—stomach cancer	2.31e-05	0.000154	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—stomach cancer	2.29e-05	0.000153	CcSEcCtD
Imatinib—Vomiting—Epirubicin—stomach cancer	2.22e-05	0.000148	CcSEcCtD
Imatinib—Nausea—Methotrexate—stomach cancer	2.22e-05	0.000148	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—stomach cancer	2.21e-05	0.000148	CcSEcCtD
Imatinib—Rash—Epirubicin—stomach cancer	2.2e-05	0.000147	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—stomach cancer	2.2e-05	0.000147	CcSEcCtD
Imatinib—Headache—Epirubicin—stomach cancer	2.19e-05	0.000146	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—stomach cancer	2.14e-05	0.000143	CcSEcCtD
Imatinib—Nausea—Epirubicin—stomach cancer	2.07e-05	0.000138	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—stomach cancer	2.05e-05	0.000137	CcSEcCtD
Imatinib—Rash—Doxorubicin—stomach cancer	2.04e-05	0.000136	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—stomach cancer	2.04e-05	0.000136	CcSEcCtD
Imatinib—Headache—Doxorubicin—stomach cancer	2.02e-05	0.000135	CcSEcCtD
Imatinib—Nausea—Doxorubicin—stomach cancer	1.92e-05	0.000128	CcSEcCtD
Imatinib—KIT—Signaling Pathways—MMP9—stomach cancer	1.78e-06	1.45e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1A—stomach cancer	1.77e-06	1.44e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—stomach cancer	1.77e-06	1.44e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—stomach cancer	1.76e-06	1.44e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—stomach cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—NOS3—stomach cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPP2R1A—stomach cancer	1.75e-06	1.43e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK1—stomach cancer	1.75e-06	1.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—stomach cancer	1.75e-06	1.42e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—stomach cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NOS3—stomach cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NOS3—stomach cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK1—stomach cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—stomach cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1A—stomach cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—stomach cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK8—stomach cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—stomach cancer	1.72e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALOX5—stomach cancer	1.71e-06	1.39e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.71e-06	1.39e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—stomach cancer	1.71e-06	1.39e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—stomach cancer	1.7e-06	1.39e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6R—stomach cancer	1.7e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—stomach cancer	1.69e-06	1.38e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—stomach cancer	1.69e-06	1.38e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—stomach cancer	1.69e-06	1.37e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NOS3—stomach cancer	1.69e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—DPYD—stomach cancer	1.69e-06	1.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—stomach cancer	1.68e-06	1.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—stomach cancer	1.68e-06	1.37e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—stomach cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1A—stomach cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—stomach cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—stomach cancer	1.67e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAV1—stomach cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOA1—stomach cancer	1.66e-06	1.35e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—stomach cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ERCC2—stomach cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—stomach cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—stomach cancer	1.65e-06	1.34e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—stomach cancer	1.65e-06	1.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—stomach cancer	1.64e-06	1.34e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—stomach cancer	1.64e-06	1.33e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—stomach cancer	1.64e-06	1.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK8—stomach cancer	1.64e-06	1.33e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NOS3—stomach cancer	1.62e-06	1.32e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—stomach cancer	1.62e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	1.61e-06	1.31e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—stomach cancer	1.61e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CD44—stomach cancer	1.6e-06	1.31e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—stomach cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK3—stomach cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TYMS—stomach cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPP2R1A—stomach cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—stomach cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—stomach cancer	1.59e-06	1.3e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—stomach cancer	1.59e-06	1.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—stomach cancer	1.59e-06	1.29e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—stomach cancer	1.58e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—stomach cancer	1.58e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—stomach cancer	1.58e-06	1.29e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—stomach cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—stomach cancer	1.57e-06	1.28e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—stomach cancer	1.57e-06	1.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TYMS—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	1.56e-06	1.27e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—stomach cancer	1.55e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—stomach cancer	1.54e-06	1.26e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—stomach cancer	1.54e-06	1.26e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—stomach cancer	1.54e-06	1.26e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—stomach cancer	1.54e-06	1.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RHOA—stomach cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—stomach cancer	1.52e-06	1.24e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK1—stomach cancer	1.52e-06	1.24e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—stomach cancer	1.52e-06	1.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—stomach cancer	1.52e-06	1.24e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—stomach cancer	1.52e-06	1.23e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	1.52e-06	1.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—stomach cancer	1.51e-06	1.23e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	1.51e-06	1.23e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—stomach cancer	1.51e-06	1.23e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—stomach cancer	1.51e-06	1.23e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—stomach cancer	1.5e-06	1.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	1.5e-06	1.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—stomach cancer	1.49e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—stomach cancer	1.49e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ERCC2—stomach cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—stomach cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—stomach cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—stomach cancer	1.48e-06	1.2e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	1.47e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.47e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—stomach cancer	1.47e-06	1.2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—stomach cancer	1.47e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—stomach cancer	1.46e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—stomach cancer	1.46e-06	1.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—stomach cancer	1.46e-06	1.19e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—stomach cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—stomach cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ERCC2—stomach cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—stomach cancer	1.44e-06	1.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK1—stomach cancer	1.44e-06	1.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—stomach cancer	1.44e-06	1.17e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—stomach cancer	1.44e-06	1.17e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—stomach cancer	1.44e-06	1.17e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—stomach cancer	1.43e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.43e-06	1.17e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOA1—stomach cancer	1.43e-06	1.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	1.43e-06	1.16e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—stomach cancer	1.42e-06	1.16e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—stomach cancer	1.42e-06	1.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—stomach cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK1—stomach cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—stomach cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO1—stomach cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—stomach cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—stomach cancer	1.39e-06	1.13e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—stomach cancer	1.39e-06	1.13e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.37e-06	1.11e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ERCC2—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPP2R1A—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—stomach cancer	1.36e-06	1.1e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ERCC2—stomach cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—stomach cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—stomach cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—stomach cancer	1.34e-06	1.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—stomach cancer	1.33e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—stomach cancer	1.32e-06	1.07e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—stomach cancer	1.32e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—stomach cancer	1.32e-06	1.07e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	1.31e-06	1.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—stomach cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOA1—stomach cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—stomach cancer	1.28e-06	1.04e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—stomach cancer	1.27e-06	1.04e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—stomach cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—stomach cancer	1.26e-06	1.02e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—stomach cancer	1.26e-06	1.02e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOA1—stomach cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—stomach cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—stomach cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—stomach cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—stomach cancer	1.25e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—stomach cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD44—stomach cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—stomach cancer	1.23e-06	1e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.23e-06	1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	1.23e-06	9.97e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	1.22e-06	9.97e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—stomach cancer	1.22e-06	9.94e-06	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—stomach cancer	1.22e-06	9.92e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—stomach cancer	1.22e-06	9.9e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	1.21e-06	9.87e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—stomach cancer	1.21e-06	9.82e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—stomach cancer	1.18e-06	9.64e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK8—stomach cancer	1.18e-06	9.63e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOA1—stomach cancer	1.18e-06	9.61e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	1.18e-06	9.61e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—stomach cancer	1.17e-06	9.55e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOA1—stomach cancer	1.17e-06	9.53e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—stomach cancer	1.17e-06	9.51e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	1.16e-06	9.42e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ERCC2—stomach cancer	1.16e-06	9.41e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—stomach cancer	1.15e-06	9.39e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—stomach cancer	1.15e-06	9.37e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—stomach cancer	1.14e-06	9.29e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—stomach cancer	1.13e-06	9.21e-06	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—stomach cancer	1.13e-06	9.18e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.12e-06	9.13e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—stomach cancer	1.1e-06	8.99e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—stomach cancer	1.1e-06	8.99e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—stomach cancer	1.09e-06	8.89e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	1.09e-06	8.89e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—stomach cancer	1.09e-06	8.85e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—stomach cancer	1.08e-06	8.82e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—stomach cancer	1.08e-06	8.81e-06	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—stomach cancer	1.08e-06	8.78e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	1.06e-06	8.66e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	1.05e-06	8.57e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—stomach cancer	1.04e-06	8.51e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—stomach cancer	1.04e-06	8.47e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—stomach cancer	1.03e-06	8.41e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—stomach cancer	1.03e-06	8.41e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—stomach cancer	1.03e-06	8.4e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—stomach cancer	1.03e-06	8.37e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—stomach cancer	1.02e-06	8.29e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—stomach cancer	1.02e-06	8.28e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—stomach cancer	1e-06	8.18e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—stomach cancer	1e-06	8.16e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOA1—stomach cancer	1e-06	8.14e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—stomach cancer	9.93e-07	8.08e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—stomach cancer	9.91e-07	8.07e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—stomach cancer	9.88e-07	8.05e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	9.84e-07	8.01e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK1—stomach cancer	9.83e-07	8e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—stomach cancer	9.83e-07	8e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—stomach cancer	9.8e-07	7.98e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—stomach cancer	9.78e-07	7.96e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—stomach cancer	9.73e-07	7.92e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—stomach cancer	9.6e-07	7.82e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	9.58e-07	7.8e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—stomach cancer	9.5e-07	7.73e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—stomach cancer	9.5e-07	7.73e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—stomach cancer	9.49e-07	7.73e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—stomach cancer	9.41e-07	7.66e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—stomach cancer	9.36e-07	7.62e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—stomach cancer	9.29e-07	7.56e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—stomach cancer	9.27e-07	7.55e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—stomach cancer	9.12e-07	7.42e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—stomach cancer	8.95e-07	7.29e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ERCC2—stomach cancer	8.92e-07	7.27e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—stomach cancer	8.9e-07	7.25e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—stomach cancer	8.87e-07	7.22e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—stomach cancer	8.81e-07	7.18e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—stomach cancer	8.69e-07	7.07e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	8.53e-07	6.95e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—stomach cancer	8.39e-07	6.83e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—stomach cancer	8.25e-07	6.72e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—stomach cancer	8.18e-07	6.66e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—stomach cancer	8.11e-07	6.61e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—stomach cancer	7.93e-07	6.45e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—stomach cancer	7.89e-07	6.43e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—stomach cancer	7.74e-07	6.3e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOA1—stomach cancer	7.72e-07	6.29e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—stomach cancer	7.58e-07	6.17e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—stomach cancer	7.55e-07	6.15e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	7.08e-07	5.77e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—stomach cancer	6.93e-07	5.65e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—stomach cancer	6.8e-07	5.54e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—stomach cancer	6.12e-07	4.98e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—stomach cancer	6.1e-07	4.97e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—stomach cancer	5.85e-07	4.76e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—stomach cancer	5.47e-07	4.46e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—stomach cancer	5.35e-07	4.36e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—stomach cancer	5.34e-07	4.35e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—stomach cancer	5.04e-07	4.1e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—stomach cancer	4.99e-07	4.06e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—stomach cancer	4.27e-07	3.47e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	3.29e-07	2.68e-06	CbGpPWpGaD
